DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Exelon (Rivastigmine Tartrate) - Published Studies

 
 



Exelon Related Published Studies

Well-designed clinical trials related to Exelon (Rivastigmine)

Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. [2012]

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. [2011.12]

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. [2011.07]

Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. [2011.04]

Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. [2011.02]

Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease. [2011.01]

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. [2010.12.23]

Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. [2010.12]

Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. [2010.11.27]

An open-label pilot study of the use of rivastigmine to promote functional recovery in patients with unilateral spatial neglect due to first ischemic stroke. [2010.10]

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. [2010.10]

Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. [2010.08]

Rivastigmine in the treatment of delirium in older people: a pilot study. [2010.08]

Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. [2010.07]

[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands] [2010.06]

Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. [2010.04]

A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. [2010.04]

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. [2010.02]

Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. [2010.01]

Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. [2010]

Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. [2010]

Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. [2010]

Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. [2010]

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. [2010]

Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. [2010]

Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. [2010]

Rivastigmine in Parkinson's disease dementia. [2009.08]

Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. [2009.08]

Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. [2009.07]

Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. [2009.07]

A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury-what it showed and taught? [2009.06]

Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. [2009.06]

Rivastigmine reduces tobacco craving in alcohol-dependent smokers. [2009.05]

Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery--a randomized controlled trial. [2009.05]

Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. [2009.04]

Long-term effects of rivastigmine capsules in patients with traumatic brain injury. [2009.02]

Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. [2008.12]

A pilot study of rivastigmine in the treatment of delirium after stroke: a safe alternative. [2008.09.20]

Effects of rivastigmine on memory and cognition in multiple sclerosis. [2008.09]

Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. [2008.09]

Rivastigmine in Parkinson's disease dementia. [2008.08]

Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia : a retrospective analysis of a double-blind trial and an open-label extension. [2008]

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2008]

Rivastigmine exposure provided by a transdermal patch versus capsules. [2007.12]

Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. [2007.10]

Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. [2007.07.24]

Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease. [2007.06]

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. [2007.06]

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. [2007.05]

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. [2007.04.04]

Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. [2007.04]

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-- rivastigmine patch versus capsule. [2007.03.22]

Rivastigmine: A placebo-controlled trial of BID and TID regimens in patients with Alzheimer's disease. [2007.03.12]

Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. [2007.03]

Two years' follow-up of rivastigmine treatment in Huntington disease. [2007.01]

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. [2006.11]

Effects of rivastigmine on cognitive function in patients with traumatic brain injury. [2006.09.12]

Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial. [2006.07]

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. [2006.04]

Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. [2006.03]

Adding Memantine to Rivastigmine Therapy in Patients With Mild-to-Moderate Alzheimer's Disease: Results of a 12-Week, Open-Label Pilot Study. [2006]

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. [2005.08]

Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study. [2005.08]

Rivastigmine for vascular cognitive impairment. [2005.04.18]

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. [2005.04.16]

Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. [2005.01.19]

A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. [2005]

Rivastigmine for dementia associated with Parkinson's disease. [2004.12.09]

Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. [2004.12]

An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. [2004.11]

Disease stage in Alzheimer disease and treatment effects of rivastigmine. [2004.07]

Rivastigmine in Alzheimer disease: efficacy over two years. [2004.07]

Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies. [2004]

Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. [2003.12]

Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. [2003.11]

[Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study] [2003.10.25]

Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. [2003.09]

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. [2003.06]

Rivastigmine in vascular dementia. [2003]

Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. [2002.12]

A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. [2002.07]

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. [2002.06]

Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. [2002.05]

Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? [2002.05]

Electrocardiographic effects of rivastigmine. [2002.05]

A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. [2002.04]

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. [2002]

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. [2002]

Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. [2001.09]

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. [2001.03]

Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. [2001.01]

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. [2000.12.16]

Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced Worsening. [2000.08]

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. [2000.03]

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. [2000]

A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). [1999.07]

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. [1999.03.06]

Well-designed clinical trials possibly related to Exelon (Rivastigmine)

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. [2012]

Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. [2012]

Pharmacologic treatment for memory disorder in multiple sclerosis. [2011.10.05]

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. [2011.10]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014